Where the predominance of melanoma is seen in White people, roughly 20 times that of Black people, the weight of later stage presentation, delayed treatment, and poorer outcomes falls on those of racial and ethnic underserved populations. A culmination of biases, disparities, and inequities continues a cycle of inadequate oncology treatment for melanoma, thus resulting in delayed diagnosis and suboptimal clinical management, prognosis, and survival rate.
In this CME Outfitters BriefCase, a faculty expert will guide learners through a patient case scenario reflective of the impact of biases, disparities, and health inequities that reduce the quality of oncology care for racial and ethnic underserved patients with melanoma. This program will provide actionable strategies, empowering attendees to recognize factors and implement changes in practice to improve melanoma treatment.
At the end of this CME/CE activity, participants should be able to recognize the impact of health inequities on patients with melanoma when crafting individual treatment strategies for optimal outcomes.
Supported by an educational grant from the Johnson & Johnson Institute and the Johnson & Johnson Family of Companies.
Physicians, physician associates (PAs), nurse practitioners (NPs), nurses/nurse navigators, pharmacists, and dietitians specializing in oncology, pathology, radiology, dermatology, and primary care
It is the policy of CME Outfitters, LLC, to ensure independence, balance, objectivity, and scientific rigor and integrity in all of their CE activities. Faculty must disclose to the participants any relationships with commercial companies whose products or devices may be mentioned in faculty presentations, or with the commercial supporter of this CE activity. CME Outfitters, LLC, has evaluated, identified, and mitigated any potential conflicts of interest through a rigorous content validation procedure, use of evidence-based data/research, and a multidisciplinary peer review process.
Dr. Mitchell reports the following financial relationships: Advisory Board: Corvus Pharmaceuticals, Inc. Consultant: Amgen Inc.; Astellas Pharma Inc.; Bristol Myers Squibb; Genentech, Inc.; and SEMA4 OpCo, Inc.
Dr. Taylor reports the following financial relationships: Advisory Board: AbbVie Inc.; Beiersdorf; Biorez; Galderma Laboratories, L.P.; GloGetter; Hugel America, Inc.; Janssen Pharmaceuticals, Inc.; L’Oreal USA; Medscape; Scientis SA; and UCB, Inc. Consultant: Arcutis Biotherapeutics; Armis Biopharma; Beiersdorf; Cara Therapeutics; EPI Health; Evolus, Inc.; Johnson & Johnson; Piction Health; and Vichy Laboratories. Grants: Pfizer Inc. Research Support: Concert Pharmaceuticals; Croma-Pharma GmbH; and Eli Lilly and Company. Speakers Bureau: BureauBeiersdorf; Evolus, Inc.; L’Oreal USA; Medscape; and MJH Life Sciences. Stock Shareholder (stock options): Armis Biopharma; GloGetter; and Piction Health. Other Financial or Material Support: McGraw Hill (book royalties) and Mercer Strategies (Board of Directors)
The following peer reviewer and CME Outfitters staff have no financial relationships:
Faculty of this CE activity may include discussions of products or devices that are not currently labeled for use by the FDA. The faculty have been informed of their responsibility to disclose to the audience if they will be discussing off-label or investigational uses (any uses not approved by the FDA) of products or devices.